Biomarkers for Acute Graft-versus-host Disease

NCT02254798 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 315

Last updated 2014-10-02

No results posted yet for this study

Summary

Validation of already described biomarkers on acute GVHD prediction and severity Fecal calprotectin and alpha 1 anti-trypsin, plasmatic RER3a, IL-8, Elafin, TNFaR1, IL-2R alpha, HGF

Conditions

  • Acute GVH Disease

Interventions

OTHER

no intervention

this is a non interventional study

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Marie Robin · Hôpital Saint-Louis

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02254798 on ClinicalTrials.gov